Conference Correspondent

Concerns Over New Multiple Myeloma Therapies

Beth Faiman expresses her main concerns regarding new treatments being studied to treat multiple myeloma. Read More ›

Hematologic Cancers, Conference Correspondent, ASH

Beth Faiman discusses why it's important to communicate with and educate patients so that they can better manage their symptoms before they become more severe. Read More ›

The Challenge of Managing Treatment-Related Toxicites

By Beth Faiman, PhD, APRN-BC, AOCN

Hematologic Cancers, Conference Correspondent, ASH

Conference Correspondent

Beth Faiman explains how she identfies side effects that her patients are experiencing in order to open the lines of communication to better address other issues the patient may not be aware of. Read More ›

Unmet Needs in Patients with Myeloma

By Beth Faiman, PhD, APRN-BC, AOCN

Hematologic Cancers, Conference Correspondent, ASH

Conference Correspondent

Patients with newly diagnosed multiple myeloma have different needs than pateints relapsed/refractory disease, and Beth Faiman addresses what some of these needs are. Read More ›

What Do Patients Ask About Daratumumab?

By Beth Faiman, PhD, APRN-BC, AOCN

Hematologic Cancers, Conference Correspondent, ASH

Conference Correspondent

Beth Faiman gets questions from her patients about daratumumab on an almost daily basis. Find out what their most asked questions are. Read More ›

Starting a Patient on Daratumumab

By Beth Faiman, PhD, APRN-BC, AOCN

Hematologic Cancers, Conference Correspondent, ASH

Conference Correspondent

Beth Faiman reviews the steps she takes upon introducing patients to daratumumab. Read More ›

Perceptions of Daratumumab Therapy

By Beth Faiman, PhD, APRN-BC, AOCN

Hematologic Cancers, Conference Correspondent, ASH

Conference Correspondent

Beth Faiman sees daratumumab as a game changer for patients with multiple myeloma. Read More ›

Managing Patients with Multiple Myeloma

By Beth Faiman, PhD, APRN-BC, AOCN

Hematologic Cancers, Conference Correspondent, ASH

Conference Correspondent

Beth Faiman reflects on the considerations involved with managing patients who have experienced multiple myeloma relapses. Read More ›

Chlorambucil plus Rituximab as Front-Line Therapy for Elderly and/or Unfit CLL Patients. Long-Term Follow-Up and Correlation with Biologic-Based Risk Stratification

ASH

Conference Correspondent

Treatment of elderly and/or unfit chronic lymphocytic leukemia (CLL) patients with chlorambucil plus rituximab was associated with low toxicity, a high overall response rate, and durable progression-free survival, suggesting that in low-risk unfit patients, this combination may be an optimal therapeutic option taking into consideration safety, efficacy, and cost. Read More ›

Differences in Healthcare Utilization in CLL Patients Treated with BR versus FCR

ASH

Conference Correspondent

Healthcare utilization of elderly chronic lymphocytic leukemia (CLL) patients who remain on bendamustine-rituximab (BR) is significantly lower than patients who remain on fludarabine, cyclophosphamide, and rituximab (FCR), with FCR-treated patients experiencing significantly more days of hospitalization, outpatient visits, and emergency department visits than BR-treated patients. Read More ›

Subscribe Today!

I'd like to receive:

Page 23 of 31

Subscribe Today!

I'd like to receive: